HCV - Experimental Treatments



•CPG10101 Improves Response to Pegylated Interferon plus Ribavirin  11/10/06
•

Lower Dose of Valopicitabine plus Pegylated Interferon Shows Antiviral Activity with Fewer Side Effects  11/10/06

•Roche Polymerase Inhibitor R1626 Demonstrates Antiviral Activity and Good Safety in Phase I Study  11/10/06
•Preclinical Study Shows ITMN-191 Plus Pegasys is Active against HCV In Vitro  11/10/06
•Pancaspase Inhibitor PF-03491390 Reduces ALT and AST Levels in Hepatitis C Patients  11/10/06





Google_______________


 

 

 

 

 

 

 

 

 

 

 

 

 

 


Conference
Main Page

Hepatitis C
FDA-Approved
Treatments

Monotherapies
Intron A
Roferon
Infergen
Pegasys
PEG-Intron

Combination
 Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin

Hepatitis B
FDA-Approved
Treatments

Baraclude
 Epivir-HBV
 Hepsera
 Intron A
 Pegasys
 Tyzeka